Next-generation sequencing is radically changing how DNA diagnostic laboratories operate. What started as a single-gene profession is now developing into gene panel sequencing and wholeexome and whole-genome sequencing (WES/WGS) analyses. With further advances in sequencing technology and concomitant price reductions, WGS will soon become the standard and be routinely offered. Here, we focus on the critical steps involved in performing WGS, with a particular emphasis on points where WGS differs from WES, the important variables that should be taken into account, and the quality control measures that can be taken to monitor the process. The points discussed here, combined with recent publications on guidelines for reporting variants, will facilitate the routine implementation of WGS into a diagnostic setting.
TA B L E 1 Critical differences between WES and WGS

WES WGS
report regarding the implementation of exome sequencing in the clinic has also been published (Matthijs et al., 2015) . Many of the points addressed by Matthijs et al. (2015) are also applicable to WGS, but the greater size and complexity of the human genome mean that there are additional issues to be considered (Table 1) . Using Matthijs et al. (2015) as a baseline, we here focus on the different technical aspects involved in sequencing a complete human genome; from DNA sample source and preparation to variant calling and description (Table 2 ), but we are also fully aware of the other clinical, ethical, and professional dimensions of such a technology (Julia, Bertier, & Cambon-Thomsen, 2016) . A key consideration, addressed elsewhere, is the need for robust processes of health technology assessment (Payne et al., 2017, in press).
Sample source
The first step in sequencing a genome is to obtain a DNA sample. There are many possible sources, each of which can influence the findings. For routine clinical purposes, a venous blood sample is usually obtained, with genomic DNA isolated from nucleated cells such as lymphocytes.
Depending on the isolation method used, such samples may also contain cell-free DNA, usually from dead cells (and would therefore be expected to have the same DNA as found in the nucleated cells). If the sample is obtained during pregnancy, there will be fetal DNA (actually derived from the placenta) present in the blood. Indeed, a recent report showed that it was possible to sequence the fetal genome solely by analyzing circulating cell-free DNA from the mother (Kitzman et al., 2012) .
Likewise, if the person providing the sample has cancer, then cells/DNA from a tumor may have been shed into the circulation. The proportion of different cell types within a blood sample can vary considerably (Whitney et al., 2003) , and it is important to note that B
and T lymphocytes will have undergone somatic rearrangements at their respective cell receptor genes. Genomic DNA isolated from these sources may appear to contain deletions at these loci, if compared with DNA from nonlymphocytic cells.
When analyzing a tumor, the issue of sample purity is a critical one, as the biopsy may contain varying amounts of contaminating nontumor tissue. In addition, it is well recognized that tumors are heterogonous, and may contain clonal subtumors within the sample (Marusyk & Polyak, 2010) .
It is also possible for non-human DNA to be present in a sample.
Low invasive methods for obtaining DNA such as buccal swabs or spit kits are often used (Freeman et al., 1997) . However, food material may contaminate DNA derived from a buccal swab or saliva sample. Additionally, bacteria such as Streptococcus parasanguinis are commonly found in the oral cavity, and may be a significant contributor to a DNA sample isolated from this source (Mahfuz, Cheng, & White, 2013) .
Potential contaminations in a specific genomic DNA sample may derive from infections of the individual (viral, bacterial, etc.) or any cell culturing when performed. This is not necessarily an issue for WES, as the enrichment step will enrich for human sequences and therefore automatically reduce the level of contamination, but most WGS protocols will sequence all DNA present in a sample, irrespective of the source.
Although cultured cells are an easy source of DNA, it is known that culturing can lead to genomic instability (Adey et al., 2013; Maitra et al., 2005; Narva et al., 2010) . In addition, depending on the stringency of the culture conditions, contaminants might be present, such as mycoplasma, yeast, and so on. It is also possible that the cell line in Chatterjee, 2007) , and many journals now require evidence that cell lines used in a report are correct. It has now become a service of a number of biobanks to verify and authenticate cell lines used in research projects, prior to the publication submission.
Another potential issue is the replication state of the cells. If DNA is isolated from proliferating cells, then DNA from early replicating regions will be over-represented in comparison with sequence from late replicating regions. This is especially important when looking at possible copy-number variants (CNV) or mosaic changes (Koren et al., 2014) .
Reports have shown that it is possible to sequence the genome of a single cell (Navin et al., 2011; Wang & Navin, 2015) and even DNA • Reference genome (build, presence/absence of different haplotypes) will affect the completeness and accuracy of alignment.
• Some loci cannot be unambiguously mapped, especially with short-read sequencing
• Unmapped reads can be due to genetic variation incompatible with standard genomic alignment, for example, certain types of structural variation
• Aligning to a reference will never lead to a complete genome
De novo assembly
• Is more accurate, but also more time-consuming and complex and RNA from the same cell (Dey, Kester, Spanjaard, Bienko, & van Oudenaarden, 2015) . Such sequences will never be complete; however, as part of the genome they will be lost during preparation and sequencing. It is also important to note that every cell has its "own" genome, even when isolated from the same tissue within a single individual, due to de novo variation introduced during growth, derived from DNA replication and/or DNA damage repair. WGS analysis of individual cells has shown significant variation, ranging from large CNVs (Cai et al., 2015; Knouse, Wu, & Amon, 2016) to LINE1 retrotranspositions (Evrony et al., 2015) .
DNA isolation
Ideally, clean and high-molecular-weight DNA will be obtained, and this will usually be the case from freshly obtained samples. Older DNA samples or those isolated from archived material may well be degraded or contaminated. DNA degradation is rarely random, meaning that genomic regions will be unequally represented. This will be reflected in nonuniform coverage of specific regions (e.g., chromosome ends, AT/GC-rich regions, etc.), and may preclude sequence analysis with long-read instruments. In fact, the data obtained can be used to monitor the extent of degradation, when present.
SEQUENCING PLATFORMS
Although there are now a number of different NGS platforms available (reviewed in Reuter, Spacek, & Snyder, 2015) , only a few are amenable for routine human WGS. These can be loosely divided into short-read (<1 kb read length) and long-read (>1 kb) sequencers. The current market leaders for short-read sequencers are the Illumina systems. Illumina sequencing chemistry is based on sequencing-by-synthesis, using nucleotides linked to fluorescently labeled terminators (Bentley et al., 2008) . Paired-end sequencing allows both ends of the molecule to be read, theoretically doubling the amount of sequence produced and potentially allowing the identification of structural variants through discordant mapping of the two ends.
Of the sequencers that can routinely produce reads >1 kb in length, the Pacific Biosciences RSII is the most commonly used for human WGS. Sequencing takes place in individual wells on a single molecule real-time (SMRT) cell. Using this approach, it is possible to produce sequence reads >50 kb in length, although with a much lower output and higher error rate than the Illumina. The error rate can be compensated for with sufficient read depth, as the errors are unbiased. This allows for regions not amenable to sequencing with Illumina chemistry, for example, homopolymer stretches or loci with high or low GCcontent, to be sequenced. Several human genomes sequenced with this technology have been described (Chaisson et al., 2015a; Zook et al., 2016) .
Another example of a long-read sequencer is the Oxford Nanopore system. This technology reads the nucleotides in a DNA strand by measuring the change in electrical current as the DNA molecule passes through a pore in a membrane. Advantages over other sequencing platforms are the low startup cost, portability, and speed from sample to data. Primarily used for smaller genomes (Loman, Quick, & Simpson, 2015; Quick et al., 2016) , the first human genome completely sequenced using this technology was announced at the end of 2016.
Sample preparation
The method of DNA isolation used determines whether specific contaminants may be present. When blood is centrifuged, cells can be separated from cell-free DNA, and other methods may be used to reduce the amount of DNA derived from viruses or bacterial contaminants.
Sample preparation mostly involves steps that depend on the sequencing platform to be used, but generally involves some form of DNA fragmentation followed by the attachment of linker sequences to facilitate the sequencing reaction. Again, fragmentation is not random, and depends on different factors, including GC-content, genomic location, and so on. Currently, popular methods using enzymatic fragmentation (transposases) are known to demonstrate some bias due to GCcontent (Lan et al., 2015; Marine et al., 2011) . In addition, the size of the DNA fragments generated will influence possibilities for haplotype construction.
A PCR step is often used during library preparation, particularly when only small amounts of starting DNA are available. However, this step will also introduce biases. A study looking at the effect of GCcontent found that there was reduced abundance of DNA fragments with extreme GC% (<10% and >60%) (Aird et al., 2011) . This could be ameliorated to a degree, by optimizing the PCR conditions with regards to temperature and DNA polymerase. Another study also showed that DNA polymerase choice can be critical in reducing bias (Dabney & Meyer, 2012) .
It is also possible to prepare a genomic DNA sample for sequencing using an amplification-free protocol. In one such approach, adapters containing the sequences necessary for attachment to the Illumina flow cell are ligated onto the fragmented DNA (Kozarewa et al., 2009 ).
Amplification during cluster generation on the flow cell enriches for sequences containing the correct adaptors. This amplification step is inherent to the Illumina sequencing system, and it is only singlemolecule sequencing platforms like Pacific Biosciences (Eid et al., 2009) and Oxford Nanopore (Clarke et al., 2009 ) that do not include some type of amplification. As every amplification step introduces biases, amplification should be restricted to a minimum (Aird et al., 2011; Kozarewa et al., 2009; van Dijk, Jaszczyszyn, & Thermes, 2014) .
Read alignment
The two main variables in read alignment are the choice of aligner and the choice of reference genome. Many different algorithms have been developed for aligning short read sequences (reviewed in Ye, Meehan, Tong, & Hong, 2015) , with Bowtie/Bowtie2 (Langmead & Salzberg, 2012; Langmead, Trapnell, Pop, & Salzberg, 2009 ) and BWA (Li & Durbin, 2009 ) among the most popular.
The reference sequence used for mapping has significant consequences, especially with regards to repeat regions, unassigned sequences (unplaced contigs), and different haplotypes (present as haplotype chromosomes or alternative alleles). Before a transition is made to a new human genome build (e.g., hg19-hg38), existing data should be analyzed relative to the old and new reference, and all differences should be understood.
Metrics of all sorts and from all stages in the pipeline can and should be stored in a QC database. The aim of such a database is to gather information about the distribution of these metrics, in order to automatically find outliers. If, for example, the GC-content of all fastq files is stored, it can be noted that the GC-content on average will be 40%, with a very small deviation (<1%). Any sample that has a GC-content that significantly deviates from this distribution should be set aside for further scrutiny. Likewise, the transition/transversion ratio can be used as a quality control for single-nucleotide polymorphisms (SNPs), which is typically higher for exons as compared with introns, and higher for synonymous SNPs compared with nonsynonymous SNPs (Wang, Raskin, Samuels, Shyr, & Guo, 2015) .
There are several important stages in the pipeline where QC metrics are gathered. In general, one should try to capture a distribution of a metric rather than one value. For example, do not store the average insert size of the library, but rather the distribution of insert sizes (using 100 bp bins).
Short-read sequencers, for example, Illumina HiSeq, produce sequence reads that are not sufficiently long to be unambiguously mapped to certain repetitive sequences in the genome, especially when they contain expanded (disease-associated) alleles. This has consequences for the analysis of, for example, CNVs/SVs in these regions, and for trinucleotide repeat disorders. Not only are repeat expansions like CGA and CGG extremely sensitive to PCR-bias, when there is insufficient unique flanking sequence present, but also the reads will not be mapped with high confidence and it is unlikely that variants will be called reliably.
Given the difficulties observed with read mapping, and the associated consequences for accurate variant calling, it might be advantageous to make a reference genome that has been optimized for diagnostic purposes. This diagnostic reference genome should be modified at all sites where read mapping is not optimal for reliable variant detection. Such regions include those underlying trinucleotide repeat expansion disorders, where the ideal reference genome would contain an extended repeat, ensuring the mapping of all reads and thereby accurate repeat-length scoring. Similarly, repeated segments of genes such as DRD4 (48 bp unit) and PRNP (48 bp unit), can be extended to improve variant detection and allele sizing. Larger duplicated sequences can be reduced to a single copy, ensuring that variants will not be missed because they are randomly distributed over the different copies. Linking variants based on this clinical reference genome to the standard reference genome build (e.g., hg38) can be achieved using a simple genomic coordinate translation table.
For quality purposes, a number of specific genomic regions should be selected and used to generate quality metrics, as well as for determining coverage and the ability to detect variants. These can be based on specific criteria, for example, high (around the promoter of EGFR [Obradovic et al., 2013] ) and low (around exon 2 of DMD [White et al., 2002] not included in exome analysis (exonic and intronic/intergenic regions, respectively). Loci not expected to be covered using the applicable sequencing approach should also be included.
Small sequence variants (SNPs/indels/STRs)
Many different algorithms have been described for calling variants in NGS data (reviewed in Nielsen, Paul, Albrechtsen, & Song, 2011) .
Comparative studies have shown that no single algorithm can detect all variants, that there is <100% overlap between algorithms, and that indels are especially difficult to detect (Cornish & Guda, 2015; Liu, Han, Wang, Gelernter, & Yang, 2013) . Analysis of short tandem repeats (Press, Carlson, & Queitsch, 2014) are complicated by the high mutation rate due to polymerase slippage. It has been shown that non-PCR amplification is better for STR analysis when compared with an amplification-based protocol, with a ninefold reduced error rate (Fungtammasan et al., 2015) .
STRUCTURAL VARIATION
There are many different types of structural variation (SV), includ- If more than one distribution is needed to explain the observed variation, a (common) CNV is detected. This approach works well if the CNV is relatively common in the input dataset. Another well-known tool, XHMM (Miyatake et al., 2015) , uses a combination of principal component analysis normalization and a hidden Markov model to detect CNVs. A relatively large number of samples (at least 50) should be used to reliably call CNVs within this set. Finally, WISECONDOR, a tool originally developed for noninvasive prenatal testing (NIPT) (Straver et al., 2014) has successfully been used to detect CNVs in WES data. This tool detects violations of correlated coverage of bins within one sample. A reference set is used to establish the correlation; the CNV detection itself is done per sample. For all of the approaches described above, either a batch of samples, or a reference set, is needed to cope with the high variability of coverage within a WES data set. Additionally, there is usually no possibility of determining the exact breakpoint, meaning that the exact nature of duplications will usually be unclear and other types of SV, for example, inversions, will not be detected. Using WGS data, especially when using amplification-free protocols, gives a more uniform coverage, making SV detection more reliable and sensitive. In addition, WGS samples should contain the unique breakpoint sequences, instrumental for resolving the identity and exact borders of the SV.
In contrast to SNPs, a relatively low level of sequence coverage is sufficient to detect many types of SV. Aneuploidies can be detected in cell-free DNA as part of NIPT (Brady et al., 2015) , with <10 million reads (<1x average coverage) being sufficient for whole chromosome aneuplodies (Chiu et al., 2008; Fan et al., 2008) . Multiallelic CNVs (mCNV) are specific genomic regions that can be present in a range of different copy numbers, and are difficult to accurately genotype (Cantsilieris & White, 2012) . A report by Handsaker et al. (2015) modified a previously published read depth approach (Handsaker, Korn, Nemesh, & McCarroll, 2011) to identify and genotype >1,000 mCNV loci in samples from the 1000 Genome Project.
UNMAPPED READS (DUSTBIN ANALYSIS)
Reads that do not initially map to the reference may still be informa- Specific algorithms have been developed for identifying inversion breakpoints in PacBio sequence data, by reanalyzing reads that did not initially align (Chaisson et al., 2015a) .
Unmapped mates and soft-clipped reads are indirect evidence of large SVs that may be translocations, but also large insertions, tandem duplications, and so on. Although analyzing these reads by themselves is not sufficient to draw any conclusions about the nature of the SV, it does indicate that there may be an aberration. Also, in combination with CNV calling, it may exclude or support certain types of events.
Some read pairs cannot be mapped to the reference genome at all.
There are several possible reasons for this, for example, the reference sequence contains too many copies of this sequence, or the reference sequence does not contain the sequence of interest. The first case is easy to detect from the alignment file; however, there are multiple potential causes for the latter case:
➢ The sequence is sample specific, or the population that this sample comes from significantly differs from the reference.
➢ The sequence comes from a different organism (contamination, an infection, etc.).
To classify these read pairs, it is possible to use a BLAST-like approach to see whether there is any significant enrichment for known pathogens. In practice, high-throughput tools like Kraken (Wood & Salzberg, 2014) or Centrifuge (Kim, Song, Breitwieser, & Salzberg, 2016) 
De novo assembly
There are several issues with assembling a genome through alignment to a reference. The reference genome will contain gaps, due to difficulties in assembling complex regions such as repeat structures. In addition, homology between repeats means that unambiguous alignment will not always be possible. Routine sequence analysis will not necessarily identify on which allele a specific variant is located (Snyder, Adey, Kitzman, & Shendure, 2015) . Whether variants are in cis (on the same allele) or in trans (on different alleles on the two chromosomes)
can have important clinical consequences. Two deleterious variants in a gene associated with a recessive condition may have no effect if they are in cis, but are likely to be disease-causing if in trans ("compound heterozygosity").
Most studies attempting to associate CNVs of a specific locus use the sum of the different alleles, rather than measuring each allele separately (White, 2015) . Although different haplotypes representing the range of copy numbers have been generated for several loci, for example, the amylase locus (Carpenter et al., 2015) , this information is not routinely available in typically used reference genomes. For WGS data, one option to obviate many of these problems is to perform a de novo assembly (Chaisson, Wilson, & Eichler, 2015b) . Although this is more complex and computationally intensive, it will produce a more complete genome. If short-read technology is used, a combination of paired-end and mate pair libraries of different sizes is costly, but advantageous, and it will still not be sufficient to completely assemble a genome. A study used the PacBio system to sequence previously uncharacterized regions of the human genome (Chaisson et al., 2015a) . Mapping long reads to the ends of gaps and assembling from these points allowed the generation of >1 Mb of previously unmapped sequence.
Independent of what sequencing technology will predominate in the future, it can be anticipated that de novo assembly will eventually be the standard approach for genome sequencing.
Variant reporting
Ultimately, whether a mapping or a de novo assembly approach is used, the sequence will be compared with a reference to detect and call variants. The HGVS recommendations for the description of sequence variants are widely accepted standards for how each type of variant should be reported. It should be noted however that the standard output from NGS is not HGVS, but typically a VCF file, a semistandard.
The problem is that in VCF the same variant can be reported in different ways. When in HGVS a one nucleotide deletion is reported as g.12345678del, in VCF it may appear as position:12345677 refGC sampleG, or position:12345678 refCT sampleT. In addition, NGS software calls deletions on the 5' site of repeated sequences, whereas the HGVS recommends the 3' rule. Needless to say that this causes errors when tools or users annotate these variants and perform database searches using previous reports, and they do not realize that one variant may be reported using different formats. Although tools are available to cope with this problem (e.g., Mutalyzer [Wildeman, van Ophuizen, den Dunnen, & Taschner, 2008] Suggestions for what is required in a clinical WGS report have been published (McLaughlin et al., 2014) . Especially when the purpose of the sequence analysis is to provide a genetic diagnosis, it is important to specify which regions have not been covered sufficiently to report any sequence variants (Brownstein et al., 2014) . This should include
(1) regions known to not be covered using the technology implemented for sequencing, for example, repetitive regions and extreme GC%, and (2) regions that did not achieve sufficient coverage to allow variants to be called.
It may be possible that WGS is being performed for nonclinical reasons, that is, out of general interest or to identify "nice-to-know"
variants. In such a case, it is essential that there are clear guidelines regarding what types of genes/variants will be analyzed, as well as what counselling (if any) will be provided when reporting the findings.
Variant analysis of WGS data
Even if the entire genome is sequenced, it may be possible that only a subset of loci is screened for variants. Largely due to biases introduced during the enrichment step, WGS provides more consistent coverage of the exonic sequences than WES for the same depth of sequence (Meynert, Ansari, FitzPatrick, & Taylor, 2014) . This can be compensated for by increasing the WES sequence depth, but this increases the cost of the assay further.
A study by Gilissen et al. (2014) both approaches, the differences were primarily due to differences in sequence coverage, with WGS giving a more uniform coverage. The discordance between WES and WGS was also described in Belkadi et al. (2015) , showing that the false-positive rate was higher in WES as compared with WGS. Interestingly, the accuracy of indel calling was similar for both, demonstrating the inherent difficulty in calling indel variants.
A report by Sun et al. (2015) focusing only on 500 genes previously implicated in ID found that WES detected all variants identified by WGS in nine samples, and that 99% of the 500 genes were covered to a sufficient depth. These findings demonstrate that the effective efficiency of WES versus WGS depends on the purpose of the analysis. However, as sequencing becomes cheaper, it will eventually be more cost-effective, from a laboratory perspective, for WGS to be the default option for genetic analysis, irrespective of how much of the genome will subsequently be analyzed. Assigning noncoding variants to a specific disease faces several challenges. In some cases, large de novo deletions or duplications upstream or downstream of a given gene can be linked to a condition with high certainty, for example, SOX9 with disorders of sex development, campomelic dysplasia, and / or craniofacial disorders (Gordon et al., 2009; Kleinjan & van Heyningen, 2005) . In most cases, however, it is not always immediately clear which gene is affected by a given noncoding variant.
The study of Taylor et al. (2015) was only able to link noncoding variants to a condition in two cases. In one, a SNV in the 5' UTR of the EPO gene, identified in two unrelated families, was the only rare exonic variant in an identical by descent, 8-Mb interval. The role of EPO in red blood cell development makes it a compelling candidate for the erythrocytosis seen in these families.
The other was a complex rearrangement near the SOX3 gene, consisting of a deletion combined with an insertion of part of chromosome 2, identified in a case with X-linked hypoparathyroidism. SOX3 is known to be involved in parathyroid development, providing a link between the affected locus and the condition. This example also highlights a strength of WGS, as the insertion would not have been detected with exome or microarray analysis.
Several consortia, such as the Encyclopedia of DNA Elements (ENCODE) project (ENCODE Project Consortium, 2012), and Roadmap Epigenomics Mapping Consortium (Roadmap Epigenomics Consortium et al., 2015) , have generated genome-wide data sets from multiple cell types that allow the identification of genomic regions that have regulatory potential. Even with this information, it is still challenging to predict the effect of a SNV. Different approaches have been described for using these data to predict functional effects (Boyle et al., 2012; Lee et al., 2015) ; however, in the vast majority of cases, it is necessary to combine these predictions with other biological information to make a link with disease.
CONCLUSIONS
Although routine WGS, as a laboratory activity, is rapidly becoming feasible from a financial viewpoint, there is currently no single sequencing technology able to generate complete, fully haplotype resolved, human genomes. The most accurate genome assemblies to date have used a combination of short-and long-range sequencers, along with other genomic assembly technologies such as optical mapping (Hastie et al., 2013) . Initiatives such as Genome In A Bottle are assembling high-quality, haplotype aware, diploid reference genomes.
These genomes can serve as superior references for mapping studies, and the approaches used can be applied more broadly for further genome-based studies. Ultimately, however, it will require the development of a technology that can sequence single DNA molecules, hundreds of kilobases in length, before complete genomes can routinely be generated, as well as considerable efforts to achieve the best benefit for patients regarding their informed choices and relevant medical service. As a common endeavor, taking the time to share data, clinical findings, and experiences with the implementation and use of different policies for these issues, whenever it is possible and appropriate to do so, is necessary. Cooperation between both doctor and patient and between research teams will be the key to achieving the successful use of this powerful tool, which offers many more challenges than the technical ones we have outlined here.
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